Description

Simple

A vitamin found in many supplement products.

Clinical

A vitamin found in many supplement products.

Overview

Ergocalciferol is an inactivated vitamin D analog.[1] It is synthesized by some plants in the presence of UVB light.[6] The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932.[7]

Ergocalciferol is considered the first vitamin D analog and is differentiated from [cholecalciferol] by the presence of a double bond between C22 and C23 and the presence of a methyl group at C24. These modifications reduce the affinity of ergocalciferol for the vitamin D binding protein resulting in faster clearance, limits its activation, and alters its catabolism.[Read more

Pharmacology

Indication

Ergocalciferol is indicated for the treatment of hypoparathyroidism, refractory rickets, and familial hypophosphatemia.[FDA label]

Hypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands. This con... Read more

Pharmacodynamic

After the activation of the vitamin D receptor, some of the biological changes produced by ergocalciferol include mobilization and accretion of calcium and phosphorus in the bone, absorption of calcium and phosphorus in the intestine, and reabsorption of calcium and phosphorus in the kidney.[ Read more

Mechanism of action

For its activity, ergocalciferol is required to be transformed to its major active circulating hydroxylated metabolite and transported to the target organs in order to bind to its target, the vitamin D receptor.[ Read more

Absorption

Ergocalciferol is absorbed in the intestine and carried to the liver in chylomicrons. Its intestinal absorption does not present limitations unless the presence of conditions related to fat malabsorption.[ Read more

Protein binding

Ergocalciferol is not found significantly distributed circulating in plasma. It is known to be found in its bound form to the vitamin D plasma protein.[ Read more

Volume of distribution

The amount of circulating ergocalciferol is very limited as this compound is rapidly stored in fat tissue such as adipose tissue, liver and muscle. This is very obvious in reports that indicate that circulating ergocalciferol is significantly reduced in obese patients.[ Read more

Clearance

There are no formal reports regarding the clearance rate of ergocalciferol. Due to the structural similarity, it is recommended to consult this parameter with [cholecalciferol]. On the other hand, the proposed renal clearance of calcitriol is of 31 ml/min.[ Read more

Half life

Ergocalciferol can be found circulation for 1-2 days. This quick turnover is presented due to hepatic conversion and uptake by fat and muscle cells where it is transformed to the active form.[ Read more

Route of elimination

The active form of ergocalciferol, calcitrol, cannot be maintained for long periods in storage tissue mainly in periods of dietary or UVB deprivation.[ Read more

Toxicity

The reported LD50 for orally administered ergocalciferol in the rat is of 10 mg/kg.[MSDS] Overdosage with this agent is reported to produce hypervitaminosis characterized by hypercalcemia, renal impairment, calcification of soft tissues, a decline in the rate of linear growth and increase in bone mi... Read more

Adverse Effects

Contraindications

  • Hypersensitivity:
    • false
  • Regions: US
  • Patient Conditions:
      • Name: Hypervitaminosis D
      • Drugbank Id: DBCOND0015762
  • Hypersensitivity:
    • false
  • Regions: US
  • Patient Conditions:
      • Name: Abnormal sensitivity to the toxic effects of vitamin D
      • Drugbank Id: DBCOND0107478
  • Hypersensitivity:
    • false
  • Regions: US
  • Patient Conditions:
      • Name: Malabsorption Syndrome
      • Drugbank Id: DBCOND0038388
  • Hypersensitivity:
    • false
  • Regions: US
  • Patient Conditions:
      • Name: Hypercalcemia
      • Drugbank Id: DBCOND0003950

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Ergocalciferol
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1alpha-Hydroxyvitamin D5
The risk or severity of adverse effects can be increased when Ergocalciferol is combined with 1alpha-Hydroxyvitamin D5.
1alpha,24S-Dihydroxyvitamin D2
The risk or severity of adverse effects can be increased when Ergocalciferol is combined with 1alpha,24S-Dihydroxyvitamin D2.
Acetyldigitoxin
The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Acetyldigitoxin.
Acetyldigoxin
The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Acetyldigoxin.
Aldosterone
The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Aldosterone.
Alfacalcidol
The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Alfacalcidol.
Aluminum hydroxide
The serum concentration of Aluminum hydroxide can be increased when it is combined with Ergocalciferol.
Beclomethasone dipropionate
The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Beclomethasone dipropionate.
Becocalcidiol
The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Becocalcidiol.
Bendroflumethiazide
The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Ergocalciferol.
Benzthiazide
The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Ergocalciferol.
Betamethasone
The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Betamethasone.
Betamethasone phosphate
The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Betamethasone phosphate.
Budesonide
The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Budesonide.
Calcifediol
The risk or severity of adverse effects can be increased when Calcifediol is combined with Ergocalciferol.
Calcitriol
The risk or severity of adverse effects can be increased when Calcitriol is combined with Ergocalciferol.
Calcium acetate
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Ergocalciferol.
Calcium carbonate
The risk or severity of adverse effects can be increased when Calcium carbonate is combined with Ergocalciferol.
Calcium cation
The risk or severity of adverse effects can be increased when Calcium cation is combined with Ergocalciferol.
Calcium chloride
The risk or severity of adverse effects can be increased when Calcium chloride is combined with Ergocalciferol.
15 References
  1. 1 . Porter A, Gilmartin C, Srisakul U, Arruda J, Akkina S: Prevalence of 25-OH vitamin D deficiency in a population of hemodialysis patients and efficacy of an oral ergocalciferol supplementation regimen. Am J Nephrol. 2013;37(6):568-74. doi: 10.1159/000351185. Epub 2013 May 30.PubMed: 23735861
  2. 2 . Lee JY, So TY, Thackray J: A review on vitamin d deficiency treatment in pediatric patients. J Pediatr Pharmacol Ther. 2013 Oct;18(4):277-91. doi: 10.5863/1551-6776-18.4.277.PubMed: 24719588
  3. 3 . Gallagher JC, Bikle DD: Vitamin D: Mechanisms of Action and Clinical Applications. Endocrinol Metab Clin North Am. 2017 Dec;46(4):xvii-xviii. doi: 10.1016/j.ecl.2017.09.001. Epub 2017 Sep 28.PubMed: 29080648
  4. 4 . Sahay M, Sahay RK: Refractory rickets in the tropics. J Pediatr Endocrinol Metab. 2010 Jun;23(6):597-601.PubMed: 20662333
  5. 5 . Hymoller L, Jensen SK: Plasma transport of ergocalciferol and cholecalciferol and their 25-hydroxylated metabolites in dairy cows. Domest Anim Endocrinol. 2017 Apr;59:44-52. doi: 10.1016/j.domaniend.2016.11.002. Epub 2016 Nov 16.PubMed: 27940098
  6. 6 . Coulston A. and Boushey C. (2008). Nutrition in the Prevention and Treatment of Disease (2nd ed.). Academic Press.
  7. 7 . Eitenmiller R., Ye L. and Landen W. (2008). Vitamin analysis for the health and food sciences (2nd ed.). Taylor and Francis.
  8. 8 . Rajiv Kumar (1984). Vitamin D: Basic and Clinical Aspects. Martinus Nijhoff Publishing.
  9. 9 . Speeckaert M., Speeckaert R., Geel N. and Delanghe J. (2014). Advances in Clinical Chemistry. Elsevier.
  10. 10 . FDA approvals Link
  11. 11 . Endocrine Web Link
  12. 12 . NORD Link
  13. 13 . Pediatric Pharmacotherapy Link
  14. 14 . Pubmed books Link
  15. 15 . Dailymed Link